Home
Clinical Trials
Comprehensive Oncology Measur...

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Last Updated: 2020-01-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-02-28

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

NCT01142674

Lymphoma, T-Cell, Peripheral

COMPLETED

A Registry for People With T-cell Lymphoma

NCT05978141

T-cell Lymphoma NK-Cell Lymphoma T-cell Prolymphocytic Leukemia +28 more

RECRUITING

Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)

NCT05237245

Lymphoproliferation Induced by HTLV-1 HTLV-1 Adult T-cell Lymphoma / Leukemia HTLV-1 Infection

RECRUITING

Transplantation After Complete Response In Patients With T-cell Lymphoma

NCT05444712

Peripheral T Cell Lymphoma

RECRUITING NA

T-Cell Project: Epidemiologic Component

NCT00705809

Peripheral T-Cell Lymphoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The COMPLETE registry is a prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices. The registry will enroll newly-diagnosed patients with PTCL treated with a variety of regimens. The COMPLETE registry is designed to better understand PTCL patient characteristics, treatments, and outcomes to help design and understand future clinical trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral T-cell Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is newly diagnosed with Peripheral T-cell Lymphoma (PTCL):

* Aggressive natural killer (NK)-cell leukemia
* Adult T-cell lymphoma/leukemia (human T-cell leukemia virus \[HTLV\] 1+)
* Angioimmunoblastic T-cell lymphoma
* Anaplastic large cell lymphoma (ALCL), primary systemic type (ALK+, ALK-)
* PTCL, not otherwise specified (NOS)
* T/NK-cell lymphoma, nasal type
* Enteropathy-type intestinal lymphoma
* Hepatosplenic T-cell lymphoma
* Subcutaneous panniculitis T-cell lymphoma
* Transformed mycosis fungoides (at diagnosis of transformation)
* T-cell prolymphocytic leukemia (T-PLL)
* Cutaneous gamma/delta (γ/δ) T-cell lymphoma
* Cutaneous aggressive CD8+ T-cell lymphoma
* Hematodermic neoplasms (blastic plasmacytoid dendritic cell neoplasm)
* Systemic Epstein Barr Virus (EBV)+ T-cell lymphomas (T-cell lymphoproliferative disorders of childhood)

Exclusion Criteria

* Patient gives written informed consent

* Patient has other T- or NK-cell malignancies including:

* Precursor T/NK neoplasms
* T-cell large granular lymphocytic leukemia
* Mycosis fungoides, other than transformed mycosis fungoides
* Sézary syndrome
* Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Francine Foss, MD

Role: STUDY_CHAIR

Yale University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

DCH Cancer Treatment Center

Tuscaloosa, Alabama, United States

Site Status

Arizona Cancer Center

Tucson, Arizona, United States

Site Status

Genesis Cancer Center

Hot Springs, Arkansas, United States

Site Status

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Site Status

City of Hope National Medical Center

Duarte, California, United States

Site Status

Moores Cancer Center UCSD

La Jolla, California, United States

Site Status

Wilshire Oncology Medical Group

La Verne, California, United States

Site Status

UCLA

Los Angeles, California, United States

Site Status

USC & Norris Cancer Center

Los Angeles, California, United States

Site Status

Stanford University Medical Center

Stanford, California, United States

Site Status

UCLA Olive View Medical Center

Sylmar, California, United States

Site Status

Danbury Hospital Praxair Cancer Center

Danbury, Connecticut, United States

Site Status

Yale University School of Medicine

New Haven, Connecticut, United States

Site Status

Washington Cancer Institute at Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

Georgetown University

Washington D.C., District of Columbia, United States

Site Status

Coral Springs Oncology

Coral Springs, Florida, United States

Site Status

Medical Specialists of the Palm Beaches

Lake Worth, Florida, United States

Site Status

Hematology Oncology Associates

Loxahatchee Groves, Florida, United States

Site Status

University of Miami

Miami, Florida, United States

Site Status

MD Anderson Orlando

Orlando, Florida, United States

Site Status

Moffit Cancer Center

Tampa, Florida, United States

Site Status

Emory University Cancer Center

Atlanta, Georgia, United States

Site Status

Georgia Cancer Specialists

Atlanta, Georgia, United States

Site Status

Medical College of Georgia

Augusta, Georgia, United States

Site Status